Bacterial Skin and Skin Structure Infections (SSSIs) Treatment Market : Technological Advancements, Evolving Industry Trends and Global Insights 2018-2024

Albany, NY, 21st May : Recent research and the current scenario as well as future market potential of "Bacterial Skin and Skin Structure Infections (SSSIs) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024" globally.

Skin and skin structure infections (SSSIs) caused by different bacteria may range from mild to severe infections. Some of the common skin and skin structure bacterial infections include carbuncles, post-surgical wound infections and traumatic wound infections.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1362738

These are one of the most common infections treated in hospital settings. These infections (SSTIs) may be caused by any of these bacteria - Staphylococcus aureus, Streptococcus pyogene, Pseudomonas aeruginosa, beta-hemolytic streptococci, Enterococcus, vancomycin-resistant enterococci, Clostridium, Escherichia coli, Klebsiella spp. and S. pyogenes. Methicillin-resistant Staphylococcus aureus (MRSA) and streptococci are the most common organisms causing skin and skin structure infections (SSSIs).

Skin and skin structure bacterial infections are classified as acute/uncomplicated and complicated infections. Simple skin and skin structure infections (SSSIs) include furuncles, cellulitis, erysipelas, superficial abscesses and wound infections, whereas complicated skin and skin structure infections (SSSIs) include myositis, gas gangrene and necrotizing fasciitis. A comorbidity such as diabetes or HIV can also lead to complicated skin and skin structure infections (SSSIs).

Global Bacterial Skin and Skin Structure Infections (SSSIs) Treatment Market: Trends and Opportunities

The market for bacterial skin and skin structure infections (SSSIs) treatment is analyzed based on the medications used for its treatment which includes antibiotics and anti-bacterial agents. Rise in the incidence of skin and skin structure infections especially in hospitals, has led to the development of resistance. Moreover, new strains of infectious bacteria urge the need for development of new therapies. For instance, vancomycin is the choice of drug against resistant Gram-positive cocci. However, increase in the minimum inhibitory concentration (MIC) and resistance to his drug has fueled the demand for new drugs. Physicians have started using linezolid, tigecycline and daptomycin for the management of complicated skin and skin structure infections (cSSSIs). The selection of an appropriate drug depends on the causative microorganism. Besides medications, surgical methods are also practiced for the treatment of skin and skin structure infections (SSSIs).

Make An Enquiry About TOC with tables & Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1362738

Rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections has led to the need for new therapies. In addition, new product developments will drive the bacterial skin and skin structure infections treatment market. Recently, in May 2014, Durata Therapeutics, Inc. announced the U.S. FDA approval of its injectable product Dalvance (dalbavancin) intended for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), in adult patients. Dalvance is the first and the only intravenous antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Global Bacterial Skin and Skin Structure Infections (SSSIs) Treatment Market: Regional Analysis

The classification of bacterial skin and skin structure infections was proposed by the U.S. FDA in 2010 in order to standardize definitions and establish objectives in assessing the clinical response within clinical trials. Based on geography, the skin and soft tissue infections treatment market is analyzed into North America, Europe, Asia-Pacific and Rest of the World. According to the SENTRY Antimicrobial Surveillance Program database, Staphylococcus aureus was the dominant pathogen, ranking highest in North America, than in Europe and Latin America. The relevant statistics has been recorded in this database over several years until 2009. Owing to the high prevalence of these infections, North America is the dominant market for the bacterial skin and skin structure infections treatment products.

Global Bacterial Skin and Skin Structure Infections (SSSIs) Treatment Market: Key Players

Some of the companies involved in the development of medications for bacterial skin and skin structure infections (SSSIs) include Furiex Pharmaceuticals, Inc., GlaxoSmithKline plc, Melinta Therapeutics, Inc, Debiopharm International S.A., MerLion Pharmaceuticals Pte Ltd., Durata Therapeutics, Inc., Paratek Pharmaceuticals, Inc. and Cempra, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis

The regional analysis covers:

North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

Browse Report @ https://www.researchmoz.us/bacterial-skin-and-skin-structure-infections-sssis-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2016-2024-report.html

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/

This release was published on openPR.